Spirulina and spinal cord injury: secondary injury, neuroprotection, and autonomic nutrition

SCI secondary injury cascade

Timeline: Primary injury is immediate and mechanical. Secondary injury unfolds over hours to weeks: haemorrhage within 2 hours, excitotoxicity peak 2–24 hours, microglial activation peak 48–72 hours, progressive apoptosis over 1–4 weeks, cyst cavity formation over months. The secondary cascade extends well beyond the primary injury site into the injury penumbra — neurons that survive the primary impact but are vulnerable to oxidative and inflammatory damage.
Microglial NOX2: Resident spinal cord microglia are activated by primary injury DAMPs. M1-polarised microglia generate NOX2-derived superoxide that kills penumbral neurons via lipid peroxidation and NF-κB-driven TNF-α/IL-1β release. Phycocyanobilin inhibits microglial NOX2, potentially reducing M1 activation and shifting microglia toward M2 (repair-oriented) polarisation. This mechanism is supported by animal SCI models showing reduced lesion volume with antioxidant interventions.
Ischaemia-reperfusion: Spinal cord vasculature disruption creates ischaemia-reperfusion cycles in the pericontusional zone. Reperfusion NOX2 in endothelial cells generates superoxide that reacts with residual NO to form peroxynitrite, damaging axon myelin. Endothelial NOX2 inhibition by phycocyanobilin may reduce this component of peroxynitrite-mediated axon damage.

Pressure ulcers and protein/iron: Pressure injuries affect 25–66% of SCI patients. Wound healing requires adequate protein (1.25–1.5 g/kg/day) and iron for collagen hydroxylation (prolyl hydroxylase, an iron-dependent enzyme). Spirulina provides complete protein (3.5 g/5 g) and non-haem iron (2–4 mg/5 g). Check iron status with transferrin saturation in SCI patients with chronic pressure ulcers.
Constipation and neurogenic bowel: Neurogenic bowel is near-universal in cervical and thoracic SCI. Spirulina polysaccharides provide prebiotic substrate that supports Lactobacillus and Bifidobacterium, assisting bowel motility regulation. Adequate fibre and hydration are the primary neurogenic bowel management pillars; spirulina contributes but does not substitute bowel management protocols.
Muscle atrophy: Denervated muscle below the level of injury undergoes rapid atrophy. Spirulina protein is leucine-rich enough to stimulate mTORC1 in innervated muscle above the injury level. For incomplete SCI with partial motor function: spirulina protein contributes to resistance exercise recovery in rehabilitation context.

Autonomic dysreflexia (cervical/upper thoracic SCI, T6 and above): Autonomic dysreflexia involves uncontrolled sympathetic storms triggered by stimuli below the injury level (bladder distension, bowel impaction, skin irritation). Blood pressure can spike to 200/130 mmHg within minutes. This is a medical emergency. Spirulina’s blood pressure-lowering effect (via NO preservation and antihypertensive mechanisms in trials) is not relevant as an acute treatment for dysreflexia but the general vasodilatory effect may contribute to reduced baseline blood pressure in SCI patients with chronic hypertension from dysreflexic episodes.
Sodium management: The Zarrouk medium used in growing does not contaminate the harvested spirulina significantly if properly rinsed. Commercial spirulina sodium content is 100–200 mg/10 g — low enough to be unproblematic in most SCI patients even those on blood pressure management.

Neurogenic bladder (incomplete emptying or reflex voiding) creates significantly elevated UTI risk in SCI. Spirulina’s GLA→DGLA pathway reduces leukotriene-mediated urothelial inflammation. Spirulina polysaccharides support Lactobacillus in the gut-urinary microbiome axis, which may reduce recurrent UTI frequency. This is supportive, not substituting for catheter hygiene protocols and antibiotic treatment of active UTIs.

Baclofen (spasticity): No pharmacokinetic interaction documented. Baclofen is not significantly CYP-metabolised.
Gabapentin/pregabalin (neuropathic pain): No pharmacokinetic interaction. Neither is CYP-metabolised.
Oxybutynin, solifenacin (neurogenic bladder): CYP3A4 substrates. No documented spirulina CYP3A4 interaction.
Anticoagulants (VTE prophylaxis is standard in acute SCI): LMWH or DOAC — see DVT/PE guidance. Spirulina vitamin K consistency rule applies if on warfarin.

Acute SCI (0–4 weeks): focus on medical management; 1–2 g/day spirulina in food is acceptable if tolerated; no active contraindication
Chronic SCI (rehabilitation and beyond): 3–5 g/day; assess iron status with transferrin saturation; complete protein contribution to wound healing and muscle mass
Powder format in smoothies or blended food preferred (dysphagia is common in cervical SCI; tablets require intact swallowing)
No interaction with baclofen, gabapentin, or oxybutynin; warfarin consistency rule applies